Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04816214
Title Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)
Acronym GEOMETRY-E
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.